01—Abstract
Summary
Summary of the 8-K filed May 6, 2025. Cited figures are marked; the original filing is the authoritative source.
International Flavors & Fragrances Inc. (IFF) reported first quarter 2025 results for the period ended March 31, 2025, in a press release furnished as Exhibit 99.1.
Reported net sales were $2.84 billiona, down 2% from the prior-year period, while currency neutral sales on a comparable basis increased 3%. The company recorded a loss before taxes of $(994) million, driven by a $1.15 billion goodwill impairment in Food Ingredients tied to the separation of the Nourish segment into Taste and Food Ingredients. Reported EPS was $(3.98), while adjusted EPS excluding amortization was $1.20 per diluted share.
Adjusted operating EBITDA was $578 millionb, a 20.3% margin, and on a comparable currency neutral basis it improved 9% year-over-year. Cash flow from operations was $127 million and free cash flow was $(52) million. Net debt to credit adjusted EBITDA was 3.9x at quarter end.
The company said it completed the divestiture of its Pharma Solutions business two months ahead of schedule, closing on May 1, 2025, which it described as a key step toward its targeted debt leverage ratio. Full-year 2025 guidance for sales of $10.6 billion to $10.9 billionc and adjusted operating EBITDA of $2 billion to $2.15 billion was maintained.
Management updated foreign exchange and Pharma Solutions divestiture impacts on growth and flagged that the outlook includes current tariff exposure but does not account for potential recessionary pressures. Management described the macroeconomic environment as highly uncertain and warned of potential additional challenges, while emphasizing productivity, innovation and customer collaboration.
02—Key points
Key Highlights
- Reported net sales of $2.84 billion, down 2% year-over-year; currency neutral comparable sales rose 3%, with growth in Taste, Pharma Solutions, Health & Biosciences and Scent.
- Loss before taxes of $(994) million, reflecting a $1.15 billion goodwill impairment in Food Ingredients related to the Nourish segment separation.
- Reported EPS of $(3.98); adjusted EPS excluding amortization of $1.20 per diluted share, compared with $1.13 in the prior-year period.
- Adjusted operating EBITDA of $578 million with a 20.3% margin; comparable currency neutral adjusted operating EBITDA improved 9%.
- Cash flow from operations of $127 million and free cash flow of $(52) million; net debt to credit adjusted EBITDA of 3.9x at quarter end.
- Pharma Solutions divestiture closed May 1, 2025, two months ahead of schedule; full-year guidance now includes four months of Pharma Solutions results.
- Full-year 2025 guidance maintained for sales of $10.6 billion to $10.9 billion and adjusted operating EBITDA of $2.0 billion to $2.15 billion; FX impact lowered to approximately 2% adverse on sales growth.
03—Questions
Frequently Asked Questions
Why did IFF report a large pre-tax loss in the first quarter of 2025?
The loss before taxes of $(994) million was driven primarily by a $1.15 billion impairment of goodwill in the Food Ingredients segment, which the filing ties to the separation of the Company's Nourish segment into Taste and Food Ingredients.
How did underlying operating performance compare with the prior year?
Reported sales fell 2% to $2.84 billion, but currency neutral comparable sales rose 3%. Adjusted operating EBITDA was $578 million, and on a comparable currency neutral basis it improved 9% year-over-year, driven by volume growth, favorable net pricing and productivity gains.
Did IFF change its 2025 financial guidance?
IFF maintained its full-year 2025 sales guidance of $10.6 billion to $10.9 billion and adjusted operating EBITDA guidance of $2 billion to $2.15 billion. It lowered its expected foreign exchange impact on sales growth to approximately 2% from 4%, and updated the Pharma Solutions impact to reflect four rather than six months of results.
What did the Pharma Solutions divestiture mean for IFF?
The company completed the divestiture of Pharma Solutions on May 1, 2025, two months ahead of schedule. Management said this milestone supports achieving its targeted debt leverage ratio, and net debt to credit adjusted EBITDA was 3.9x at March 31, 2025.
What risks did management highlight for the rest of 2025?
Management cited heightened macroeconomic uncertainty and said the environment has potential for more challenges. The guidance includes current tariff exposure but does not account for potential recessionary pressures from recent trade policy shifts.
04—Continue